ConductScience.org, home

Paper36765765

The Evolution of Ki-67 and Breast Carcinoma: Past Observations, Present Directions, and Future Considerations.

Finkelman BS and 3 others. Cancers (Basel), 2023. Cited by 49 papers, by iCite.

Cite this record

ConductScience Library. The Evolution of Ki-67 and Breast Carcinoma: Past Observations, Present Directions, and Future Considerations. Papers, record 36765765. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36765765

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The Evolution of Ki-67 and Breast Carcinoma: Past Observations, Present Directions, and Future Considerations.
PubMed
Journal
Cancers (Basel)
PubMed
Year
2023
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
49
iCite
Relative citation ratio, by iCite
5.48
iCite
Revised in PubMed
2024-09-12
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Finkelman BSBrian Shttps://orcid.org/0000-0002-4348-8208
2Zhang HHuina
3Hicks DGDavid G
4Turner BMBradley Mhttps://orcid.org/0000-0002-3103-0179

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References184

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
121297447Proliferation (Ki-67 and phosphohistone H3) and oncotype DX recurrence score in estrogen receptor-positive breast cancer.Appl Immunohistochem Mol Morphol2011https://conductscience.org/library/papers/21297447PubMed
235384873
A Standardized Investigational Ki-67 Immunohistochemistry Assay Used to Assess High-Risk Early Breast Cancer Patients in the monarchE Phase 3 Clinical Study Identifies a Population With Greater Risk of Disease Recurrence When Treated With Endocrine Therapy Alone.
Appl Immunohistochem Mol Morphol2022https://conductscience.org/library/papers/35384873PubMed
328721378Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration.NPJ Breast Cancer2016https://conductscience.org/library/papers/28721378PubMed
435955851
Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist's Decision on Systemic Therapy in a Real-World Setting.
Int J Mol Sci2022https://conductscience.org/library/papers/35955851PubMed
515591335A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.N Engl J Med2004https://conductscience.org/library/papers/15591335PubMed
63020096Growth fractions in breast cancers determined in situ with monoclonal antibody Ki-67.J Clin Pathol1986https://conductscience.org/library/papers/3020096PubMed
732300181Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer.Mod Pathol2020https://conductscience.org/library/papers/32300181PubMed
830523750Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.J Clin Oncol2019https://conductscience.org/library/papers/30523750PubMed
910837136The Ki-67 protein: fascinating forms and an unknown function.Exp Cell Res2000https://conductscience.org/library/papers/10837136PubMed
1024498305Prognostic value of Ki-67 in breast cancer patients with positive axillary lymph nodes: a retrospective cohort study.PLoS One2014https://conductscience.org/library/papers/24498305PubMed
1123958221
WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial.
Trials2013https://conductscience.org/library/papers/23958221PubMed
1216899776Concordance among gene-expression-based predictors for breast cancer.N Engl J Med2006https://conductscience.org/library/papers/16899776PubMed
1328045625
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
J Clin Oncol2017https://conductscience.org/library/papers/28045625PubMed
1421372600Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis.Oncology2010https://conductscience.org/library/papers/21372600PubMed
1523584595Prognostic impact of Ki-67 labeling indices with 3 different cutoff values, histological grade, and nuclear grade in hormone-receptor-positive, HER2-negative, node-negative invasive breast cancers.Breast Cancer2015https://conductscience.org/library/papers/23584595PubMed
1625778295Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer.J BUON2015https://conductscience.org/library/papers/25778295PubMed
1732879492Chromosome clustering by Ki-67 excludes cytoplasm during nuclear assembly.Nature2020https://conductscience.org/library/papers/32879492PubMed
186706431The long-term prognostic significance of the thymidine labelling index in breast cancer.Int J Cancer1984https://conductscience.org/library/papers/6706431PubMed
1930395177Breast Cancers With Magee Equation Score of Less Than 18, or 18-25 and Mitosis Score of 1, Do Not Require Oncotype DX Testing: A Value Study.Am J Clin Pathol2019https://conductscience.org/library/papers/30395177PubMed
2018230798Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.J Natl Cancer Inst2008https://conductscience.org/library/papers/18230798PubMed

See all 184 referencesDownload CSV of references

Cited by31

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 49 citations.

PMIDTitleJournalYearIn PapersSource
42923317Immunohistochemical Expression of Proliferating Cell Nuclear Antigen in Invasive Breast Carcinoma: Associations With Histological Grade and Ki-67 Expression.Cureus2026https://conductscience.org/library/papers/42923317PubMed
42861134Moran's index habitat and peritumoral radiomics based on digital breast tomosynthesis for predicting Ki-67 status in breast cancer.Quant Imaging Med Surg2026https://conductscience.org/library/papers/42861134PubMed
42618942Predicting ki-67 expression in breast cancer via transformer and multiple instance learning on DCE-MRI.Cancer Imaging2026https://conductscience.org/library/papers/42618942PubMed
42487966Study on the predictive efficacy of Ki-67, ER, and PR levels on the effectiveness of neoadjuvant chemotherapy in breast cancer.Front Med (Lausanne)2026https://conductscience.org/library/papers/42487966PubMed
42316062Distinguishing Ki67 stratification expression in ER-positive/HER2-negative breast cancers: comparison of advanced MRI diffusion models.BMC Med Imaging2026https://conductscience.org/library/papers/42316062PubMed
42192906Artificial Intelligence in Oncology: A Comprehensive Cross-Cancer Translational Readiness Analysis Across 18 Malignancies.Cancers (Basel)2026https://conductscience.org/library/papers/42192906PubMed
42174497Noninvasive prediction of Ki67 proliferation index in breast cancer based on integrated photoacoustic imaging.BMC Med Imaging2026https://conductscience.org/library/papers/42174497PubMed
42088208Predicting dynamic changes of Ki-67 in breast cancer after neoadjuvant therapy based on multi-phase DCE-MRI delta-radiomics.Front Oncol2026https://conductscience.org/library/papers/42088208PubMed
41948524Prognostic Value of Ki-67 and Progesterone Receptor for Risk Stratification and Outcomes by Adjuvant Chemotherapy in Early Luminal-Type Breast Cancer.Breast Cancer (Dove Med Press)2026https://conductscience.org/library/papers/41948524PubMed
41728598A pathology-based surrogate model for chemotherapy decision-making in intermediate-risk luminal breast cancer: validation of histologic grade and Ki67 in a Chinese population.Front Med (Lausanne)2026https://conductscience.org/library/papers/41728598PubMed
41215873Predictors and nomogram for upstaging to invasive breast carcinoma in ductal carcinoma in situ diagnosed by ultrasound-guided core needle biopsy.Gland Surg2025https://conductscience.org/library/papers/41215873PubMed
41149862Omission of Sentinel Lymph Node Biopsy in Early-Stage HER2+ and Triple-Negative Breast Cancer: A Retrospective Analysis.J Pers Med2025https://conductscience.org/library/papers/41149862PubMed
41114097Contrast-enhanced ultrasound as a non-invasive diagnostic modality for pancreatic ductal adenocarcinoma: The question of Ki67 for study validation.World J Gastrointest Oncol2025https://conductscience.org/library/papers/41114097PubMed
40951896Predictive value of serum glutathione S-transferase (GST-â), P-glycoprotein (PGP), P53, KI-67 in breast cancer: A systematic review and meta-analysis.J Med Biochem2025https://conductscience.org/library/papers/40951896PubMed
40734715Androgen Receptor and Tumor-Associated Neutrophil Expression Across Breast Cancer Subtypes: Associations With Clinicopathological Characteristics.Int J Breast Cancer2025https://conductscience.org/library/papers/40734715PubMed
40448815Ki-67 and 21-gene recurrence score assay in decision making for adjuvant chemotherapy in breast cancer patients.Discov Oncol2025https://conductscience.org/library/papers/40448815PubMed
40361968Advanced Deep Learning Approaches in Detection Technologies for Comprehensive Breast Cancer Assessment Based on WSIs: A Systematic Literature Review.Diagnostics (Basel)2025https://conductscience.org/library/papers/40361968PubMed
40235755The value of morphological magnetic resonance imaging features combined with diffusion kurtosis imaging for predicting Ki-67 expression levels in high-grade gliomas.Quant Imaging Med Surg2025https://conductscience.org/library/papers/40235755PubMed
40201702Proliferative Markers in Breast Cancer and Chemotherapy Implications: A Comprehensive Review.Health Sci Rep2025https://conductscience.org/library/papers/40201702PubMed
39964132Imaging-Based Prediction of Ki-67 Expression in Hepatocellular Carcinoma: A Retrospective Study.Cancer Med2025https://conductscience.org/library/papers/39964132PubMed

See all 31 cited byDownload CSV of cited by

Genes15

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36765765

GET https://conductscience.org/api/papers/v1/36765765/references?page=2